Later evolution after cardiac transplantation in Chagas' disease
Related Experiment Video
Updated: Aug 15, 2026

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
Published on: January 27, 2019
A I Fiorelli1, N A G Stolf, R Honorato
1Heart Institute of Medicine, School of Sao Paulo University, Sao Paulo, Brazil. fiorelliai@uol.com.br
Insights
Reducing immunosuppression in cardiac transplant patients with Chagas' disease significantly lowered disease reactivation and neoplasms. Early diagnosis and treatment of reactivation prevented myocardial damage, improving outcomes.
Area of Science:
- Cardiology
- Transplantation Immunology
- Infectious Diseases
Background:
- Chagas' disease poses unique challenges in cardiac transplantation.
- Reactivation of Chagas' disease post-transplant is a significant concern.
- Optimizing immunosuppression is crucial for managing Chagas' disease in transplant recipients.
Purpose of the Study:
- To report accumulated experience with cardiac transplantation in Chagas' disease.
- To emphasize the impact of immunosuppression on disease reactivation and mortality.
- To evaluate outcomes related to immunosuppression strategies and disease management.
Main Methods:
- Retrospective analysis of 59 patients undergoing cardiac transplantation for Chagas' disease.
- Inclusion of patients meeting established recipient selection criteria.
- Monitoring for Chagas' disease reactivation through parasitic identification and serological exams.
Main Results:
- Reduced immunosuppressant doses correlated with improved patient outcomes.
- Decreasing immunosuppression significantly decreased Chagas' disease reactivation.
- Mortality included infections, allograft dysfunction, rejection, neoplasms, and disease reactivation.
Conclusions:
- Early diagnosis and treatment of Chagas' disease reactivation prevent myocardial sequelae.
- Lowering immunosuppression effectively reduces disease reactivation and neoplasm incidence.
- Combined transplantation is feasible with careful immunosuppressant management.
Objective:
This research reported the accumulated experience with cardiac transplantation in Chagas' disease, emphasizing reactivation, immunosuppression, and mortality.
Methods:
Fifty-nine patients undergoing cardiac transplantation had Chagas' disease with classically accepted recipient selection criteria. In this series, 84.7% of the patients were functional class IV; 36.0% used vasopressor support; and 13.5% mechanical circulatory assistance. One patient received a heart and kidney transplantation.
Results:
After the initial experience the doses of immunosuppressants were significantly reduced with improvement in outcomes. The diagnosis of the reactivation of disease was documented by the identification of parasite in the myocardium, or on subcutaneous or serological exams. Reactivation of disease was significantly reduced by decreasing the immunosuppression. Immediate mortality occurred in 10 cases: three infections, two allograft dysfunction, two rejections, and two sudden deaths. Subsequent mortality happened in 14 patients: four by lymphoma, three by infection, two by Kaposi's sarcoma two by rejection, two by constrictive pericarditis, and one by reactivation of disease in the brain.
Conclusions:
There's no correlation between the disease and pre- or postoperative prophylaxis. The early diagnosis and specific treatment of reactivation did not leave functional sequelae in the myocardium. Reduction in immunosuppression significantly reduced reactivation of disease and neoplasms. The combined transplantation can be realized safely with more care about the immunosuppressants.
Related Concept Videos
American Trypanosomiasis
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy
